AbbVie has entered into an exclusive licensing agreement with Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, to develop and commercialize ISB 2001—a trispecific T-cell engager targeting BCMA, CD38, and CD3—for relapsed or refractory multiple myeloma. 

Under the terms, AbbVie will acquire rights to ISB 2001 across North America, Europe, Japan, and Greater China, providing IGI with a $700 million upfront payment and up to $1.225 billion in milestone payments. 

ISB 2001, currently in Phase 1 trials, has demonstrated an overall response rate of 84% in patients naive to CAR-T or T-cell engager therapies, and 71% in those previously treated, including those refractory to anti-CD38 therapy.

This collaboration enhances AbbVie's oncology pipeline, which includes over 20 investigational assets, and leverages IGI's BEAT® platform for multispecific antibody development.